Cell permeable bioactive peptide conjugates

Details Cell permeable bioactive peptide conjugates Cell permeable bioactive peptide conjugates

2011-04-19

2011-04-19

Cordero Garcia, Marcela M (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C530S325000

Reexamination Certificate

active

07928186

ABSTRACT:
Cell permeable bioactive peptide conjugates having a first bioactive peptide region coupled to a second transport peptide region allowing transfer of the first bioactive peptide region and the second transport peptide region across biological membranes to enter intact living cells for regulation of biological responses.

REFERENCES:
patent: 5441936 (1995-08-01), Houghten et al.
patent: 5968512 (1999-10-01), Tuomanen et al.
Frankel et al. Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1. PNAS, Oct. 1989. pp. 7397-7401.
Bulaj. Formation of disulfide bonds in proteins and peptides. Biotechnology Advances. (2005), vol. 23, pp. 87-92.
Annis et al. Disulfide Bond Formation in Peptides. Methods in Enzymology, vol. 289, pp. 198-221.
French et al. What is a Conservative Substitution? J Mol Evol. 1983, pp. 171-175.
Annis et al. Disulfide Bond Formation in Peptides. Current protocols in Protein Science. 2001. 18.6.1-18.6.19.
Bachvarov et al., Agonist-Induced Receptor Internalization; The Journal of Pharmacology and Experimental Therapeutics; vol. 297, No. 1, 19-26 (2001).
Bonny et al., Cell-Permeable Peptide Inhibitors of JNK; Diabetes, vol. 50, 77-82; Switzerland (Jan. 2001).
Borsello et al., A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxity and cerebral ischemia; Nature Medicine, vol. 9,1180-1186, (Sep. 2003).
Boykins et al., Cutting Edge: A Short Polypeptide Domain of HIV-1-Tat Protein Mediates Pathogenesis, The Journal of Immunology, 163:15-20 (1999).
Brand et al., HIV-1 Tat Protein Is a Substrate and Inhibitor of PKR; The Journal of Biological Chemistry, vol. 272, No. 13, 8388-8395 (Mar. 28, 1997).
Chang et al., Dissecting Endogenous 5-HT2c Receptor Signaling Pathways; The Journal of Biological Chemistry, vol. 275, No. 10, 7021-7029, (Mar. 10, 2000).
Farrell et al., Ingibition of Epstein-Barr virus-induced growth proliferation by anuclear antigen EBNA2-Tat peptide; PNAS, vol. 101 No. 13, 4625-4630 (Mar. 30, 2004).
Feligioni et al., Tat-Evoked Ach Release in Human and Rat Brain; The Journal of Neuroscience, vol. 23 No. 17, 6810-6818 (Jul. 30, 2003).
Joliot et al., Transduction peptides' from technology to physiology; Nature Cell Biology, vol. 6 No. 3, 189-196 (Mar. 2004).
Kaneto et al., Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide; Nature Medicine, vol. 10 No. 10, 1128-1132 (Oct. 2004).
Kaushik et al., Anti-tar PNA inhibits HIV-1 in Culture; Journal of Virology, vol. 76 No. 8, 3881-3891 (Apr. 2002).
Kubota et al., NF-kB Inhibition Reduces Sleep; Am J Physiol Regulatory Intergrative Comp Physiol, vol. 279, R404-R413, (Feb. 25, 2000).
Lin et al., Nuclear Translocation of NF-kB Inhibited by Cell-permeable Peptide; The Journal of Biological Chemistry, vol. 270 No. 24, 14255-14258 (Jun. 16, 1995).
Liu et al., Peptide-directed Suppression of Cytokine Response; The Journal of Biological Chemistry, vol. 275 No. 22,16774-16778 (Jun. 2, 2000).
Lu et al., Angiotensin II-Induced Nuclear Targeting of the Angiotensin Type 1 Receptor in Brain Neurons; Endocrinology, vol. 139 No. 1, 365-375 (1998).
Takenobu et al., p53 Protein Transduction Therapy; Molecular Cancer Therapeutics, vol. 1, 1043-1049 (Oct. 2002).
Wang et al., Cell Permeable Bel-2 Binding Peptides; Cancer Research 60, 1498-1502 (Mar. 15, 2000).
Weihofen et al., Structure of HIV-1 Tat(1-91) bound to DPPIV; JBC Papers in Press., 13 total pages, (Jan. 28, 2005).
Y. Hashimoto, et al., Proc. Natl. Acad. Sci. U.S.A., 98, 6336 (2001).
“Site-specific effects of apelin-13 in the rat medulla oblongata on arterial pressure and respiration” Auton Neurosci. 101(1-2):32-8 (2002).
“Ghrelin causes hyperphagia and obesity in rats”, A.M. Wren et al. Diabetes 50(11):2540-7 2001.
“Gut hormone PYY(3-36) physiologically inhibits food intake”, R.L. Batterham et al. Nature 418(6898):650-654 (2002).
“Enhanced inhibitory feeding response to alpha-melanocyte stimulating hormone in the diet-induced obese rat”, M.J. Hansen, et al., Brain Res. 892(1):130-137 (2001).
“Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing . . . ”, Zsuzsanna et al. Cancer, vol. 88, Issue 6, 1384-1392 (2000).
“Hemodynamic Effects of Human Atrial Natriuretic Peptide After Modified Fontan Procedure”, Takeshi Hiramatsu, MD, et al., Ann Thorac Surg 1998;65:761-764.
“Encapsulated transgene cells attenuate hypertension, cardiac hypertrophy and enhance renal . . . ” Li-Guo Chen et al. The Journal of Gene medicine 6:786-797 (2004).
“Cardiovascular Effects of Brain Natriuretic Peptide in Essential Hypertension”, Giorgio La Villa, et al., Hypertension, 25, 1053-1057 (1995).
Kristensen, P. et al., Nature 393, 72-76 (1998).
J Biol Chem. Feb. 15, 1991;266(5):2897-902.
“Identification of Receptors for Neuromedin U and its Role in Feeding” Howard et al. Nature 406, 70-75 (Jul. 6, 2000).
“Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons”, S.L. Dickson, et al., Neuroscience. Mar. 1993;53(2):303-6.
“Mitochondrial coupling factor 6 as a potent endogenous vasoconstrictor” Tomohiro Osanai, et al., J. Clin. Invest. 108(7) 1023-1030 (2001).
Norvartis Pharmaceuticals Corporation, East Hanover, New Jersey, Publication T2002-82 (2002).
“Hemodynamic actions of systemically injected pituitary adenylate cyclase activating . . . ”, E.J.Whalen, et al., European Journal of Pharm. vol. 366, No. 2, pp. 205-215 (1999).
“An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis . . . ” Y. Guo, et al, Cancer Res. 202 Aug. 15; 62(16):4678-84.
Larsen PJ, Vrang N, Tang-Christensen M. Curr Pharm Des. 2003;9 (17):1373-82.
Currier, E.A., et al., Biochemical Pharmacology, vol. 67, No. 7.
Young LH, et al. Am J Physiol Heart Circ Physiol. 279(4):H1453-9 (2000).
Zaidi, M. et al., Critical Reviews in Clinical Laboratory Sciences 28, No. 2, 109 (1990).
“Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus” David S. Ludwig, et al., Am J Physiol Endocrinol Metab 274: E627-E633, 1998.
“Adrenomedullin: a smart road from pheochromocytoma to treatment of pulmonary hypertension.” M. Westphal, M. Booke and A.T. Dinh-Xuan Eur Respir J 24;518:520 (2004).
Koken et al. Intracellular Analysis of In Vitro Modified HIV Tat Protein. The Journal of Biological Chemistry, 1994; 269(11), pp. 8366-8375.
Löhr et al. Small HIV-1-Tat Peptides Inhibit HIV Replication in Cultured T-cells. Biochemical and Biophysical Research Communications, 2003; 300, pp. 609-613.
Tian et al. Continuous Solid-Phase Synthesis and Disulfide Cyclization of Peptide-PNA-Peptide Chimeras. Organic Letters, 2002; 4(23), pp. 4013-4016.

Affiliated with

Also associated with

Rating

Cell permeable bioactive peptide conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cell permeable bioactive peptide conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell permeable bioactive peptide conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2718995